Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 3/20 | 0.51 |
| ▸ | REN | P00797 | 4/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426250 | 0.88 | CASP3 (0.58) | CTSDRENCASP3CASP1CASP7 | |
| SCHEMBL5174682 | 0.87 | REN (0.39) | CTSDRENKLK5 | |
| SCHEMBL27564532 | 0.87 | CTSK (0.59) | RENCTSLCTSS | |
| SCHEMBL625910 | 0.84 | CTSD (0.44) | CTSDRENCASP3KLK5CASP6 | |
| SCHEMBL10073352 | 0.84 | CTSD (0.44) | CTSDRENCASP3KLK5CASP6 | |
| SCHEMBL4434235 | 0.84 | CTSD (0.44) | CTSDRENCASP3KLK5CASP6 | |
| SCHEMBL14269200 | 0.83 | SYK (0.52) | KLK5CASP1CTSLCTSSSYK | |
| SCHEMBL8414721 | 0.82 | CASP3 (0.52) | CTSDRENCASP3KLK5CTSL | |
| SCHEMBL5493054 | 0.81 | CASP3 (0.58) | CTSDCASP3CASP1CASP7CASP9 | |
| SCHEMBL5174687 | 0.81 | SYK (0.42) | KLK5CTSSSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157430-B2 | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-6949516-B2 | Dipeptide apoptosis inhibitors and the use thereof | CYTOVIA, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050192231-A1 | Dipeptide apoptosis inhibitors and the use thereof | KEANA JOHN F (US) | 2005-09-01 | — | — | US | disclosed |
| US-20040259804-A1 | (Substituted)Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1033910-A4 | DIPEPTIDE APOPTOSIS INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030181391-A1 | Dipeptide apoptosis inhibitors and the use thereof | CYTOVIA, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6596693-B1 | Reduce or prevent premature death of cells of the immune system, cardiovascular system, nervous system etc. | CYTOVIA, INC. | 2003-07-22 | — | — | US | disclosed |
| CN-1313846-A | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases | IDUN PHARMACEUTICALS INC (US) | 2001-09-19 | — | — | CN | disclosed |
| US-6184210-B1 | DIPEPTIDE-BASED CASPASE (PROTEOLYTIC FAMILY OF CYSTEINE PROTEASES WHOSE ACTIVE SITE CYSTEINE RESIDUE IS ESSENTIAL FOR ICE-MEDIATED APOPTOSIS) INHIBITORS OF GIVEN FORMULA ARE POTENT INHIBITORS OF APOPTOSIS | CYTOVIA, INC. | 2001-02-06 | — | — | US | disclosed |
| EP-1033910-A1 | DIPEPTIDE APOPTOSIS INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999018781-A1 | DIPEPTIDE APOPTOSIS INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181391-A1 | Dipeptide apoptosis inhibitors and the use thereof | API5, CASP3, APAF1 | CTSD 1206/4885REN 396/4885CASP3 2/4885 |
| US-20050192231-A1 | Dipeptide apoptosis inhibitors and the use thereof | API5, CASP3, BAD | CTSD 955/4885REN 679/4885CASP3 2/4885 |
| US-20040259804-A1 | (Substituted)Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | CTSD 145/4885REN 2079/4885CASP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.